Xinying Zeng
4221-116 Xiang'an South Road
Xiamen, 361102, China
Xiamen, 361102, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Development of a Novel Approach for In Vivo Tumor Hypoxia PET Imaging with Nitroreductase-Specific Responsive Radiotracers.
Journal: Molecular pharmaceutics
Published: February 18, 2026
Small-Molecule Radiotracers for Visualization of V-Domain Immunoglobulin Suppressor of T Cell Activation.
Journal: Journal of medicinal chemistry
Published: September 21, 2024
Development and Evaluation of [68Ga]Ga-Labeled Riboflavin Derivative for RFVT3-Targeted PET Imaging of Melanoma in Mice.
Journal: Molecular pharmaceutics
Published: September 16, 2024
Development of STING probes and visualization of STING in multiple tumor types.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 13, 2024
MicroPET Imaging of Riboflavin Transporter 3 Expression in Myocardial Infarction/Reperfusion Rat Models with Radiofluorinated Riboflavin.
Journal: ACS pharmacology & translational science
Published: March 27, 2024
Progressive Optimization of Lanthanide Nanoparticle Scintillators for Enhanced Triple-Activated Radioluminescence Imaging.
Journal: Angewandte Chemie (International ed. in English)
Published: January 24, 2024
A proof-of-concept study on bioorthogonal-based pretargeting and signal amplify radiotheranostic strategy.
Journal: Journal of nanobiotechnology
Published: November 19, 2023
Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03.
Journal: European journal of nuclear medicine and molecular imaging
Published: October 30, 2023
Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 12, 2023
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 25, 2022
Last Updated: 09/26/2026